

A Carbohydrate-Derived Splice Modulator

Sachin Dhar,[†] James J. La Clair,^{*,†} Brian León,[†] Justin C. Hammons,[†] Zhe Yu,[‡] Manoj K. Kashyap,[‡] Januario E. Castro,[‡] and Michael D. Burkart^{*/}

[†]Department of Chemistry and Biochemistry, University of California–San Diego, 9500 Gilman Drive, La Jolla, California 92093-0358. United States

[‡]Moores Cancer Center, University of California–San Diego, La Jolla, California 92093-0358, United States

Supporting Information

ABSTRACT: Small-molecule splice modulators have recently been recognized for their clinical potential for diverse cancers. This, combined with their use as tools to study the importance of splice-regulated events and their association with disease, continues to fuel the discovery of new splice modulators. One of the key challenges found in the current class of materials arises from their instability, where rapid metabolic degradation can lead to off-target responses. We now describe the preparation of bench-stable splice modulators by adapting



INTRODUCTION

In 2007, two Japanese teams revealed the importance of targeting the SF3b unit of the spliceosome for antitumor therapy.^{1,2} These breakthroughs not only forwarded the spliceosome as an important target for cancer² but also identified two key families of polyketide spliceosome modulators (Figure 1), including FD-895 (1a),² pladienolide B (1b),³ and herboxidiene (1c).⁴ Since these discoveries, the development of splicing assays has been instrumental in the advance of next generation splice modulators. The success of these discoveries was further marked by the translation of an analog of pladienolide D, E7101, into phase I clinical trials.⁵ However, many of these natural products are subject to low stability and/ or poor pharmacological properties.⁶ To this end, our laboratory has been part of a growing medicinal chemistry effort to identify next generation splice modulators with improved pharmacological properties.

An attractive proposal developed by Webb suggested a method of analog development through the use of a consensus motif.⁷ Pursuing this approach, their team has advanced the sudemycins⁸ and a pladienolide-herboxidiene hybrid⁹ as nextgeneration leads. This, along with efforts at the Eisai Co., Ltd.,¹⁰ H3 Biomedicine,¹¹ Pfizer,¹² Ghosh-Jurica laboratories,¹³ Koide laboratory,¹⁴ and our laboratories,¹⁵ have provided a strong foundation for achieving analogs with improved pharmacological properties. We now report on an advanced new class of splice modulators that are more potent, stable, and rapidly accessible analogs.

In addition to carbohydrates being ubiquitous biological scaffolds, they are also derived from the natural chiral pool, making them ideal scaffolds for medicinal chemical optimization.¹⁶ To expand on this hypothesis, we designed and prepared carbohydrate-derived 2, an analog of FD-895 whose core was derived from D-glucose.

RESULTS

Our design began with FD-895 (1a) because of the fact that earlier medicinal chemistry efforts in our laboratory provided derivatives with improved pharmacological properties.^{6a} From these studies, we determined that manipulation of the stereochemistry at the C16–C17 diad (blue shaded, Figure 1) provided an effective means to improve activity. From this data, we targeted a side chain that contained the exact terminus (orange shading, Figure 1), epoxide (green shading, Figure 1), and diene groups (green shading, Figure 1) as one of our more active analogs of FD-895.6ª Here, we incorporated already known SAR data to improve activity by selecting an improved C16-C17 stereodiad (blue shading in 2, Figure 1).

Clues Obtained from the Solution Structure Analysis of FD-895 (1a). Although structural information on the eukaryotic spliceosome has recently been published,18 representation of the binding of a splice modulator with SF3b has yet to be established. We began by exploring the solution structure of the macrolide core of FD-895 (1a). Using multiple solvents $(CDCl_3 \text{ and } C_6D_6)$ for data acquisition, we identified a series of NOE interactions that along with coupling constant data allowed assignment of the solution structure of the macrolide core (Figure 2a).

Design of a Carbohydrate Core Motif. Using this structure and analyzing its space-filling model, we began to search for motifs that accurately represented the macrolide core. Our goal was to find a structural unit that offered an improved

Received: December 23, 2015



Figure 1. Structures of FD-895 (1a), pladienolide B (1b), herboxidiene (1c), and carbohydrate-derived splicing modulator 2. Compound 2 contains the terminus (orange) of 1a, the epoxide and diene of 1a (green), and a core derived from 1c (gold).

synthesis entry and diverse means of tailoring while also addressing previous pharmacological issues (stability and solubility). We began by inspecting the overlap between the small herboxidiene (1c) and large FD-895 (1a) cores. Although a clear overlay existed (Figure 1b,c), it was evident that space occupied by the C4–C7 unit within 1a may not be a requirement for activity. We soon realized that simple monosaccharides such as D-glucose could provide a strong overlap with these cores. After evaluating several structures, we turned our attention to explore α -methyl-2,3,4-trimethoxy-Dglucopyranoside (3) as a core mimetic.¹⁹

Structurally, glycoside 2 offered a functional map that lay between the core sizes of 1a and 1c (Figure 2). As illustrated in Figure 2d,e, the C2–C4 methoxy groups in 2 provided a fit approximating 1a relative to that of herboxidiene (Figure 2b,c). Specifically, the C2 methoxy group of 2 filled the space taken by the C24 methyl group in 1a. Likewise, the C3 methoxy of 2 was able to partially fill the space of the C29–C30 acetate, a region that was already shown to tolerate functional modifications.²⁰ With this support, we turned our attention to synthesize and biologically evaluate analog 2.

Synthetic Strategy. Our plan focused on using a late-stage Julia–Kocienski olefination to couple a side chain derived from FD-895 to the monosaccharide core (see Abstract graphic). Here, we envisioned that we could leverage the extensive efforts from our own laboratory for development of pladienolide/FD-895 side chain^{6a,15b} as a means to probe the structure–activity relationships (SARs) of side-chain-incorporating analogs. We therefore set out toward preparation of core component **8** (Scheme 1) and side-chain component **16** (Scheme 2).

Synthesis of a Carbohydrate Core Component 8. Synthesis of 8 was accomplished in five steps from 3, a monosaccharide derivative that in turn was prepared in three



Figure 2. Models of FD-895 (1a, blue), herboxidiene (1c, magenta), and carbohydrate-derived analog 2 (green). (a) Derived solution structure of the FD-895 core motif as determined by evaluation of ¹H coupling constants and NOE interactions. NOE interactions were observed both on the top face (red) and bottom face (blue). Data shown was collected from ¹H, ¹H NOESY spectral data of 1a in CDCl₃ and C₆D₆ at 23 °C. (b) Model depicting the structure of 1a (blue) superimposed on the surface of 1c (magenta). (c) Model depicting the structure of 1a (blue). (d) Models depicting the structure of 1a (blue) superimposed on the surface of 1 (blue) superimposed on the surface of 1 (blue) superimposed on the surface of 1 (blue). The structure of 2 (green) superimposed on the surface of 1a (blue). The structure of the core motif in 1a was determined via NMR spectroscopy. Structures of 1b and 1c were modeled by energy minimization.¹⁷

Scheme 1. Synthesis of Core Component 8



Article

Scheme 2. Synthesis of Side Chain Component 16



steps (54% yield) from α -methyl-D-glucopyranoside.¹⁹ We began by oxidizing to aldehyde 4. Advantageously, we were able to reduce chromatographic purification efforts by using a combination of an IBX oxidation followed by solvent-dependent filtration through a pad of SiO₂. The addition of MeLi to crude 4 occurred with minimal byproduct formation, providing alcohol 5 in 82% yield from 3.

Repetition of the IBX oxidation procedure provided ketone 6, which could be rapidly purified by passage through a SiO₂ plug. Although small samples of 6 were purified for characterization, the crude product was readily subjected to a Horner–Wadsworth–Emmons olefination to afford ester 7. We were able to convert 5 to 7 in two steps and 80% yield with a single purification. Finally, ester 7 was reduced with DIBAL-H to afford core unit 8, which could be stored for months at -20 °C without decomposition. Overall, this process provides access to 8 in 66% in five steps from 3 (36% in 8 steps from α -methyl-D-glucopyranoside).

Synthesis of the Side Chain Component 16. The synthesis of the side chain component began with allylic alcohol 9, an intermediate that was prepared at >10 g scale for the synthesis of FD-895 (1a).^{6a} Allylic oxidation with MnO_2 provided aldehyde 10, which was purified through a SiO₂ plug and directly submitted to a Crimmins aldol reaction with auxiliary 11, to afford adduct 12 in 87% yield over two steps. NMR analyses on the crude product indicated that this reaction occurred without detectable formation of other isomeric products.

With 12 in hand, the carbinol was protected as TBS ether 13, and the auxiliary was removed by NaBH₄ reduction. Optimization studies indicated that a 5:1 ratio of THF:CH₃OH provided a reproducibly high yield of 14. Completion of this component was accomplished by a two-step installation of the 1-phenyl-1*H*-tetrazol-5-yl (PT) sulfone. Although Mitsunobu conditions were effective at producing sulfone 15 in 82% yield at a gram scale, oxidation often provided significant quantities of the corresponding sulfoxides (incomplete oxidation byproducts). Typically, samples of these sulfoxides were collected after chromatographic purification and resubmitted to the oxidation conditions to afford a combined yield of 89% of component 16. To date, we have completed the synthesis of gram quantities of

16 in 6 steps and 58% overall yield from 9 and 12 steps and 21% overall yield from auxiliary $11.^{6a}$

Component Assembly and Completion of the Synthesis of 2. With components 8 and 16 in hand, the component coupling began by oxidizing allylic alcohol 8 to the corresponding aldehyde 17. Purification via dry column vacuum chromatography using Geduran 60 silica gel was sufficient to afford pure 17 for coupling. After initial screening, we found the optimum yield (68%) of 18 was obtained when applying 1.05 equiv NaHMDS to 1.0 equiv of sulfone 8 and following this by addition of 1.1 equiv of aldehyde 17. The yield of this reaction also included recovery of 8% of sulfone 16 and 11% of the chromatographically separable cis isomer of 18 (structure not shown). With samples of pure 18 on hand, deprotection with TBAF afforded alcohol 19 (Scheme 3).

Scheme 3. Component Assembly



Next, we turned to the stereoselective VO(acac)₂-catalyzed epoxidation of allylic alcohols²¹ to install the C12–C13 epoxide. As shown in Figure 3a, treatment of **19** with 4.5 equiv of tBuOOH and 3 equiv of VO(acac)₂ at -20 °C for 6 h provided the desired stereoisomer with ~4:1 diastereoselectivity. Although this was the major product, over-warming or not starting the reaction at -78 °C resulted in epoxidation at C8–C9. This product was not as stable because the C11 carbinol was capable of attacking the C8 center of the epoxide, forming the corresponding furan analog (structure not shown). Although additional optimization efforts will be required, the current conditions returned **2** in 52% yield with only traces of the undesired C8–C9 epoxidation (5–10% yield).

Validation of the Structural Assignment of 2. Although the mechanism of the VO(acac)₂/tBuOOH epoxidation



Figure 3. Stereoselectivity of the C12–C13 epoxidation. (a) Expanded LC-MS trace via UV monitoring at 288 nm depicting the reaction product from treatment of 19 with VO(acac)₂/tBuOOH (blue). (b) Comparable LC-MS trace depicting the formation of two isomers by *m*-CBPA epoxidation (red). (c) Expansion of the ¹H NMR spectra of epoxide 2 from VO(acac)₂/tBuOOH in CDCl₃ (blue). (d) Expansion of the ¹H NMR spectra of epoxide 20 in CDCl₃ from m-CBPA (red). Traces of 2 denoted by a blue asterisk could not be completely removed from 20 because of close retention times.

suggests delivery of the correct stereochemical outcome, we wanted to gain further confirmation that the product was indeed **2**. We began by exploring other epoxidation conditions to prepare samples of the alternate isomer. Treatment of **19** with 1.2 equiv of *m*-CPBA at -78 °C in NaHCO₃-buffered CH₂Cl₂ followed by slow warming to room temperature afforded a ~1:1 mixture of both epoxides (Figure 3b) in 62% yield. After chromatographic purification, we were able to obtain samples of both isomers.

Comparative NMR analyses on the epoxides from VO- $(acac)_2/tBuOOH$ and *m*-CPBA provided a solution (Figure 3c). Using 2D NMR data set (Supporting Information), we were able to fully assign the proton assignments in this product. We identified that the chemical shift and coupling patterns of the epoxide protons at C12–C13 provided the closest match to the configuration of corresponding C16–C17 isomer **1e** (Figure 4), with comparable chemical shifts and coupling constants.

Stability and Solubility of 2. Early studies indicated that **2** was more soluble and stable in aqueous buffers than FD-895



Figure 4. Coupling constant analyses. NMR analysis in C_6D_6 provided a coupling pattern at C12–C13 in 2 (blue) that matched that from the corresponding FD-895 analog 1e (green) but not analogs 1a, 1f, or 1g (black).^{6a,15b}

(1a). Using capillary NMR and solvent ¹³C satellites (QSCS) as a means of quantitation,²² we found that **2** was soluble up to 95 \pm 5 mM D₂O/DMSO-*d*₆ (10:1) at 23 °C, whereas FD-895 (1a) was limited to 15 \pm 5 mM under the same conditions. Additionally, we used NMR monitoring to show that although 1a had a half-life of ~70 h in D₂O/DMSO-*d*₆ (10:1) at 37 °C,^{6a} carbohydrate analog **2** showed no signs of decomposition even after 744 h (1 month) under the same conditions. Although detailed partitioning, permeability, and metabolic stability analyses are ongoing, this initial evidence suggests that **2** offers the potential to improve pharmacological properties of this class of splice modulator.

Epoxide 2 Displays Potent Activity in Primary CLL-B Cells in Contrast to Its Precursor Alkene 19. We then screened the activity of **19** and **2** in primary CLL-B cells obtained from two CLL patients that displayed potent in vitro cytotoxic response (Figure 1), measured in the form of specific induced apoptosis (% SI), to **1a** (IC₅₀ value of 54.1 ± 7.5 nM) and **1b** (IC₅₀ value of 84.4 ± 1.2 nM). Interestingly, these studies indicated that alkene **19** did not display any activity (IC₅₀ value >50 μ M in both sets of cells). Epoxide **2**, however, was active (IC₅₀ value of 153.0 ± 11.8 nM) with ~3-fold loss of activity when compared to FD-895 (**1a**).

Compound 2 Modulates Splicing. We then turned to RT-PCR analysis to determine if the activity of **2** also included a splice response comparable to **1a** and **1b** in CLL-B cells. Using unspliced *RNU6A* and unmodulated *GAPDH* (top, Figure 5) as controls, we were able to obtain complementary splice modulation in all six genes selected from our prior studies to provide a diversity of intron retention (IR) response.^{15a} This included comparable modification of IR in *DNAJB1, ARF4, PRPF4, RIOK3, SF3A1,* and *U2AF2* (Figure 4 and S2) from primary CLL-B cells. In contrast, alkene precursor **19** was inactive for all six genes (Figure 5), indicating that the epoxide in **2** is essential for activity.

Additionally, we were able to confirm that compound 2 also induced alternate splicing (AS) events. As shown in Figure 6,

Journal of the American Chemical Society



Figure 5. Compound **2** induces splice modulation via intron retention (IR) comparable to FD-895 (**1a**) and pladienolide B (**1b**) in CLL-B cells. The alkene precursor **19**, which was shown inactive in screening assays, did not induce IR. Genes *GAPDH* and *RNU6A* were used as unspliced and loading controls, respectively. Complementary qRT-PCR data has been provided in Figure S2.

treatment of CLL-B cells with 1a, 1b, and 2 resulted in a decrease in the long (anti-apoptotic) form and increased the expression of short (pro-apoptotic) form of *MCL1*. Similarly, *BCL-X* demonstrates comparable AS events (Figure 6). This indicates that cell death induced by 1a, 1b, and 2 is not exclusively derived through AS of *MCL1* but may also include other players. This fact is further supported by RNAseq analyses,^{15a} which implicates the involvement of other pathways. Efforts are now underway to explore the roles of IR and AS events as well as to identify structural motifs that enrich specific events.





Figure 6. Compound 2 modulates alternate splicing (AS) in CLL-B cells, which is comparable to FD-895 (1a) and pladienolide B (1b). The alkene precursor 19, which was shown inactive in screening assays, did not induce AS. H2A gene was used as unspliced loading control as depicted. S and L denote short and long isoforms, respectively.

CONCLUSIONS

We now describe the preparation of a carbohydrate-derived spliceosome inhibitor **2** in a total of 22 steps, with the 12 longest linear steps from common building blocks (auxiliary **11**, D-glucose and propionaldehyde). Although complete in vitro and in vivo pharmacological analyses are underway, this analog's improved solubility, along with improved solubility in aqueous buffers, suggests an important advance in optimization of splice modulators.

Overall, this development offers several medicinal chemical benefits. First, it demonstrates that the pyran or macrolide core commonly associated with the known spliceosome inhibitors can be replaced with materials directly available from monosaccharides in the chiral pool. Second, it provides a means to prepare highly stable materials that lack rapid degradation and/or metabolic instability. Third, the use of a carbohydrate motif offers ready access to explore the SAR contained within the core unit (macrolide of 1a and 1b or pyran in 1c, Figure 1). Here, one can envision application of the described route to provide derivatives with expanded functionality at the anomeric C1 center and stereoisomers at C1-C4 positions and to explore the use of deoxygenated materials and alternative ethers at C1-C4. Although to date there has been no structural information on the complex of any established splice modulator with the Sf3b component of the spliceosome, the subsequent integration of a rational design could deliver a carbohydrate-derived splice modulator with enhanced binding and reduced pharmacological risk.

ASSOCIATED CONTENT

S Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.5b13427.

Experimental procedures, characterization data for all new compounds, and full acknowledgments. (PDF)

AUTHOR INFORMATION

Corresponding Authors

*jlaclair@ucsd.edu

*mburkart@ucsd.edu

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was support by financial support from the Lymphoma Research Foundation (#285871), the NIH (PO1-CA081534), the University of California–San Diego Foundation Blood Cancer Research Fund and the Bennett Family Foundation. B. L. was supported by the NIH IRACDA K12 (GM068524) award. We thank Dr. Yongxuan Su for mass spectral analyses and Drs. Anthony Mrse and Xuemei Huang for assistance with acquiring NMR spectral data. We thank Prof. Thomas J. Kipps for providing the CLL patient-derived cells.

REFERENCES

(1) (a) Kotake, Y.; Sagane, K.; Owa, T.; Mimori-Kiyosue, Y.; Shimizu, H.; Uesugi, M.; Ishihama, Y.; Iwata, M.; Mizui, Y. *Nat. Chem. Biol.* **2007**, *3*, 570. (b) Kaida, D.; Motoyoshi, H.; Tashiro, E.; Nojima, T.; Hagiwara, M.; Ishigami, K.; Watanabe, H.; Kitahara, T.; Yoshida, T.; Nakajima, H.; Tani, T.; Horinouchi, S.; Yoshida, M. *Nat. Chem. Biol.* **2007**, *3*, 576. (c) Hasegawa, M.; Miura, T.; Kuzuya, K.; Inoue, A.; Won Ki, S.; Horinouchi, S.; Yoshida, T.; Koseki, K.; Mino, K.; Sasaki, R.; Yoshida, M.; Mizukami, T. *ACS Chem. Biol.* **2011**, *6*, 229. (d) Bonnal, S.; Vigevani, L.; Valcarcel, J. *Nat. Rev. Drug Discovery* **2012**, *11*, 847.

(2) Seki-Asano, M.; Okazaki, T.; Yamagishi, M.; Sakai, N.; Takayama, Y.; Hanada, K.; Morimoro, S.; Takatsuki, A.; Mizoue, K. *J. Antibiot.* **1994**, 47, 1395.

(3) (a) Mizui, Y.; Sakai, T.; Iwata, M.; Uenaka, T.; Okamoto, K.; Shimizu, H.; Yamori, T.; Yoshimatsu, K.; Asada, M. *J. Antibiot.* **2004**, *57*, 188. (b) Asai, N.; Kotake, Y.; Niijima, J.; Fukuda, Y.; Uehara, T.; Sakai, T. *J. Antibiot.* **2007**, *60*, 364.

(4) Salient examples of this family also include spliceostatin A, FR901465, meayamycin, and herboxidiene (GEX1A, 1c), as described within the following: (a) Miller-Wideman, M.; Makkar, N.; Tran, M.; Isaac, B.; Biest, N.; Stonard, R. J. Antibiot. 1992, 45, 914. (b) Sakai, Y.; Yoshida, T.; Ochiai, K.; Uosaki, Y.; Saitoh, Y.; Tanaka, F.; Akiyama, T.; Akinaga, S.; Mizukami, T. J. Antibiot. 2002, 55, 855. (c) Liu, X.; Biswas, S.; Berg, M. G.; Antapli, C. M.; Xie, F.; Wang, Q.; Tang, M. C.; Tang, G. L.; Zhang, L.; Dreyfuss, G.; Cheng, Y. Q. J. Nat. Prod. 2013, 76, 685. (d) Nakajima, H.; Sato, B.; Fujita, T.; Takase, S.; Terano, H.; Okuhara, M. J. Antibiot. 1996, 49, 1196–203. (e) Meng, F.; McGrath, K. P.; Hoveyda, A. H. Nature 2014, 513, 367.

(5) For reports on the clinical trials on E7101, consult (a) Hong, D. S.; Kurzrock, R.; Naing, A.; Wheler, J. J.; Falchook, G. S.; Schiffman, J. S.; Faulkner, N.; Pilat, M. J.; O'Brien, J.; LoRusso, P. *Invest. New Drugs* **2014**, *32*, 436. (b) Dehm, S. M. *Clin. Cancer Res.* **2013**, *19*, 6064.

(6) (a) Villa, R.; Kashyap, M. K.; Kumar, D.; Kipps, T. J.; Castro, J. E.; La Clair, J. J.; Burkart, M. D. *J. Med. Chem.* **2013**, *56*, 6576. (b) Lagisetti, C.; Palacios, G.; Goronga, T.; Freeman, B.; Caufield, W.; Webb, T. R. *J. Med. Chem.* **2013**, *56*, 10033. (c) Albert, B. J.; Sivaramakrishnan, A.; Naka, T.; Czaicki, N. L.; Koide, K. *J. Am. Chem. Soc.* **2007**, *129*, 2648.

(7) Lagisetti, C.; Pourpak, A.; Jiang, Q.; Cui, X.; Goronga, T.; Morris, S. W.; Webb, T. R. *J. Med. Chem.* **2008**, *51*, 6220.

(8) (a) Convertini, P.; Shen, M.; Potter, P. M.; Palacios, G.; Lagisetti, C.; de la Grange, P.; Horbinski, C.; Fondufe-Mittendorf, Y. N.; Webb, T. R.; Stamm, S. *Nucleic Acids Res.* **2014**, *42*, 4947. (b) Webb, T. R.; Joyner, A. S.; Potter, P. M. *Drug Discovery Today* **2013**, *18*, 43. (c) Fan, L.; Lagisetti, C.; Edwards, C. C.; Webb, T. R.; Potter, P. M. ACS Chem. Biol. **2011**, *6*, 582–9. (d) Lagisetti, C.; Palacios, G.; Goronga, T.; Freeman, B.; Caufield, W.; Webb, T. R. J. Med. Chem. **2013**, *56*, 10033.

(9) Lagisetti, C.; Yermolina, M. V.; Sharma, L. K.; Palacios, G.; Prigaro, B. J.; Webb, T. R. ACS Chem. Biol. 2014, 9, 643.

(10) Kanada, R. M.; Itoh, D.; Nagai, M.; Niijima, J.; Asai, N.; Mizui, Y.; Abe, S.; Kotake, Y. *Angew. Chem., Int. Ed.* **2007**, *46*, 4350.

(11) Arai, K.; Buonamici, S.; Chan, B.; Corson, L.; Endo, A.; Gerard, B.; Hao, M. H.; Karr, C.; Kira, K.; Lee, L.; Liu, X.; Lowe, J. T.; Luo, T.; Marcaurelle, L. A.; Mizui, Y.; Nevalainen, M.; O'Shea, M. W.; Park, E. S.; Perino, S. A.; Prajapati, S.; Shan, M.; Smith, P. G.; Tivitmahaisoon, P.; Wang, J. Y.; Warmuth, M.; Wu, K. M.; Yu, L.; Zhang, H.; Zheng, G. Z.; Keaney, G. F. *Org. Lett.* **2014**, *16*, 5560.

(12) (a) He, H.; Ratnayake, A. S.; Janso, J. E.; He, M.; Yang, H. Y.; Loganzo, F.; Shor, B.; O'Donnell, C. J.; Koehn, F. E. J. Nat. Prod. 2014, 77, 1864–70. (b) Eustáquio, A. S.; Janso, J. E.; Ratnayake, A. S.; O'Donnell, C. J.; Koehn, F. E. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, E3376.

(13) (a) Ghosh, A. K.; Veitschegger, A. M.; Sheri, V. R.; Effenberger, K. A.; Prichard, B. E.; Jurica, M. S. Org. Lett. **2014**, *16*, 6200. (b) Ghosh, A. K.; Chen, Z. H.; Effenberger, K. A.; Jurica, M. S. J. Org. Chem. **2014**, 79, 5697. (c) Ghosh, A. K.; Ma, N.; Effenberger, K. A.; Jurica, M. S. Org. Lett. **2014**, *16*, 3154–7. (d) Effenberger, K. A.; Anderson, D. D.; Bray, W. M.; Prichard, B. E.; Ma, N.; Adams, M. S.; Ghosh, A. K.; Jurica, M. S. J. Biol. Chem. **2014**, *289*, 1938.

(14) (a) Larrayoz, M.; Blakemore, S. J.; Dobson, R. C.; Blunt, M. D.; Rose-Zerilli, M. J.; Walewska, R.; Duncombe, A.; Oscier, D.; Koide, K.; Forconi, F.; Packham, G.; Yoshida, M.; Cragg, M. S.; Strefford, J. C.; Steele, A. J. Leukemia 2016, 30, 351. (b) Schreiber, C. A.; Sakuma, T.; Izumiya, Y.; Holditch, S. J.; Hickey, R. D.; Bressin, R. K.; Basu, U.; Koide, K.; Asokan, A.; Ikeda, Y. PLoS Pathog. 2015, 11, e1005082. (c) Gao, Y.; Trivedi, S.; Ferris, R. L.; Koide, K. Sci. Rep. 2014, 4, 6098. (d) Gao, Y.; Koide, K. ACS Chem. Biol. 2013, 8, 895. (e) Gao, Y.; Vogt, A.; Forsyth, C. J.; Koide, K. ChemBioChem 2013, 14, 49. (f) Visconte, V.; Rogers, H. J.; Singh, J.; Barnard, J.; Bupathi, M.; Traina, F.; McMahon, J.; Makishima, H.; Szpurka, H.; Jankowska, A.; Jerez, A.; Sekeres, M. A.; Saunthararajah, Y.; Advani, A.S.; Copelan, E.; Koseki, H.; Isono, K.; Padgett, R. A.; Osman, S.; Koide, K.; O'Keefe, C.; Maciejewski, J. P.; Tiu, R. V. Blood 2012, 120, 3173. (g) Osman, S.; Albert, B. J.; Wang, Y.; Li, M.; Czaicki, N. L.; Koide, K. Chem. - Eur. J. 2011, 17, 895. (h) Albert, B. J.; McPherson, P. A.; O'Brien, K.; Czaicki, N. L.; Destefino, V.; Osman, S.; Li, M.; Day, B. W.; Grabowski, P. J.; Moore, M. J.; Vogt, A.; Koide, K. Mol. Cancer Ther. 2009, 8, 2308.

(15) (a) Kashyap, M. K.; Kumar, D.; Villa, R.; La Clair, J. J.; Benner, C.; Sasik, R.; Jones, H.; Ghia, E. M.; Rassenti, L. Z.; Kipps, T. J.; Burkart, M. D.; Castro, J. E. *Haematologica.* **2015**, *100*, 945. (b) Villa, R.; Mandel, A. L.; Jones, B. D.; La Clair, J. J.; Burkart, M. D. Org. Lett. **2012**, *14*, 5396.

(16) (a) Ernst, B.; Magnani, J. L. Nat. Rev. Drug Discovery 2009, 8, 661. (b) Jensen, K. J.; Brask, J. Biopolymers 2005, 80, 747. (c) Schweizer, F. Angew. Chem, Int. Ed. 2002, 41, 230.

(17) Structures were generated by positioning the atoms within the molecule using the known NOE correlations and minimizing with MM2 energy minimization. Efforts are now underway to complete a detailed solution structure of 1a, 1b, and 2.

(18) Yan, C.; Hang, J.; Wan, R.; Huang, M.; Wong, C. C.; Shi, Y. Science 2015, 349, 1182.

(19) (a) Noel, A.; Delpech, B.; Crich, D. Org. Lett. 2012, 14, 4138.
(b) Collins, D. J.; Hibberd, A. I.; Skelton, B. W.; White, A. H. Aust. J. Chem. 1998, 51, 681. (c) Pinilla, I. M.; Martínez, M. B.; Galbis, J. A. Carbohydr. Res. 2003, 338, 549. (c) Matwiejuk, M.; Thiem, J. Chem. Commun. 2011, 47, 8379.

(20) For instance, the first clinical lead, E-7101, bears a carbamate in place of the C29-C30 acetate; see Eskens, F. A.; Ramos, F. J.; Burger, H.; O'Brien, J. P.; Piera, A.; de Jonge, M. J.; Mizui, Y.; Wiemer, E. A.; Carreras, M. J.; Baselga, J.; Tabernero, J. *Clin. Cancer Res.* **2013**, *19*, 6296.

(21) (a) Nunes, C. D.; Vaz, P. D.; Félix, V.; Veiros, L. F.; Moniz, T.; Rangel, M.; Realista, S.; Mourato, A. C.; Calhorda, M. J. *Dalton Trans.* **2015**, 44, 5125. (b) Rodríguez-Berríos, R. R.; Torres, G.; Prieto, J. A. *Tetrahedron* **2011**, 67, 830.

(22) Dalisay, D. S.; Molinski, T. F. J. Nat. Prod. 2009, 72, 739.